Search hospitals > North Carolina > Statesville
Novant Health Cancer Institute - Statesville
Claim this profileStatesville, North Carolina 28625
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Recurrence
Conducts research for Non-Small Cell Lung Cancer
39 reported clinical trials
6 medical researchers
Summary
Novant Health Cancer Institute - Statesville is a medical facility located in Statesville, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Novant Health Cancer Institute - Statesville is involved with conducting 39 clinical trials across 108 conditions. There are 6 research doctors associated with this hospital, such as Judith O. Hopkins, Demetria I. Jacks, Joshua Trinidad, and Judy A. Tjoe.Area of expertise
1Cancer
Global LeaderStage IV
HER2 positive
alkaline phosphatase
2Breast Cancer
Global LeaderER positive
HER2 positive
HER2 negative
Top PIs
Judith O. HopkinsNovant Health Forsyth Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
9 reported clinical trials
35 drugs studied
Demetria I. JacksNovant Health Cancer Institute1 year of reported clinical research
Studies Oropharyngeal Cancer
Studies Cancer
4 reported clinical trials
7 drugs studied
Joshua TrinidadGSK Investigational Site7 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Carcinoma
3 reported clinical trials
15 drugs studied
Judy A. TjoeNovant Health Breast Surgery - Greensboro7 years of reported clinical research
Studies Breast Cancer
Studies Carcinoma
3 reported clinical trials
7 drugs studied
Clinical Trials running at Novant Health Cancer Institute - Statesville
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Lung Carcinoma
Cancer
Mantle Cell Lymphoma
Recurrence
Lymphoma
Neoplasm
B-Cell Lymphoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
T-DM1 + Tucatinib
for Breast Cancer
This phase III trial studies how well trastuzumab emtansine (T-DM1) and tucatinib work in preventing breast cancer from coming back (relapsing) in patients with high risk, HER2 positive breast cancer. T-DM1 is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called DM1. Trastuzumab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as HER2 receptors, and delivers DM1 to kill them. Tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving T-DM1 and tucatinib may work better in preventing breast cancer from relapsing in patients with HER2 positive breast cancer compared to T-DM1 alone.
Recruiting1 award Phase 313 criteria
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Novant Health Cancer Institute - Statesville?
Novant Health Cancer Institute - Statesville is a medical facility located in Statesville, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Recurrence, Non-Small Cell Lung Cancer and other specialties. Novant Health Cancer Institute - Statesville is involved with conducting 39 clinical trials across 108 conditions. There are 6 research doctors associated with this hospital, such as Judith O. Hopkins, Demetria I. Jacks, Joshua Trinidad, and Judy A. Tjoe.